Financial Performance - The company's operating revenue for 2024 was ¥863,976,571.55, a decrease of 13.89% compared to ¥1,003,376,637.04 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥6,690,166.26, representing a decline of 124.19% from ¥27,659,463.93 in the previous year[22] - The net profit after deducting non-recurring gains and losses was -¥15,563,890.23, down 143.94% from ¥35,421,382.66 in 2023[22] - The basic earnings per share for 2024 was -¥0.01, a decrease of 125.00% from ¥0.04 in 2023[22] - The weighted average return on net assets was -0.65%, down from 2.72% in the previous year[22] - The company reported a significant decline in both net profit and revenue, indicating potential challenges in its operational performance[22] - In Q1 2024, the company reported revenue of approximately ¥179.28 million, which increased to ¥278.56 million in Q2, but decreased to ¥205.24 million in Q3 and ¥200.90 million in Q4[26] - The net profit attributable to shareholders was ¥2.28 million in Q1, rising to ¥6.83 million in Q2, but turned negative with a loss of ¥3.37 million in Q3 and ¥12.43 million in Q4[26] - The total revenue for 2024 was approximately ¥863.98 million, representing a decrease of 13.89% compared to ¥1,003.38 million in 2023[61] Cash Flow and Assets - The net cash flow from operating activities increased by 35.57% to ¥64,278,831.37, compared to ¥47,414,104.46 in 2023[22] - Total assets at the end of 2024 reached ¥2,249,238,967.54, an increase of 5.43% from ¥2,133,478,855.05 at the end of 2023[22] - The net assets attributable to shareholders decreased by 0.71% to ¥1,025,895,578.65 from ¥1,033,194,655.74 in 2023[22] - The total cash inflow from financing activities increased by 38.94% to ¥680,067,649.83 in 2024, up from ¥489,464,280.26 in 2023[76] - The company's total assets included cash and cash equivalents of ¥209,467,279.68, accounting for 9.31% of total assets at the end of 2024[78] Government Support and Non-Recurring Gains - The company received government subsidies amounting to ¥5.63 million in 2024, up from ¥3.98 million in 2023, indicating a positive trend in government support[27] - The total non-recurring gains and losses for 2024 amounted to approximately ¥8.87 million, a significant recovery from a loss of ¥7.76 million in 2023[27] Market and Product Development - The pharmaceutical manufacturing industry in China is projected to maintain a revenue of ¥2.53 trillion in 2024, with a slight profit decline of 1.1%[30] - The company anticipates further market expansion and product innovation in response to the evolving healthcare landscape and consumer demands[30] - The health beverage market is expected to grow from ¥190 billion in 2019 to ¥310 billion by 2025, driven by health trends and innovative products[34] - The company has established a three-tier collaborative marketing network covering various regions in China, focusing on cardiovascular, ENT, and pediatric respiratory diseases, enhancing its competitive edge in these specialized treatment areas[35] - The core product, Sanqi Tongshu Capsule, was selected for the National Traditional Chinese Medicine Procurement Alliance in 2024 and is recommended in the "Guidelines for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition)"[35] Research and Development - The company has applied for and acquired a total of 203 patents, with 168 authorized patents, including 4 international invention patents[47] - The company is advancing the development of a new product, Sanqi Tongshu Capsule, aimed at enhancing clinical value and market presence[73] - The number of R&D personnel increased to 166 in 2024, representing a growth of 23.88% compared to 134 in 2023[75] - R&D investment amounted to ¥28,178,452.75 in 2024, a decrease of 11.67% from ¥31,902,380.11 in 2023[75] Operational Efficiency and Management - The organization implemented a flat management structure to enhance operational efficiency, focusing on customer needs and market-driven strategies[59] - The company plans to strategically divest its steel structure business to concentrate resources on the core pharmaceutical industry[57] - The company has established a financial management center with a strict accounting system, ensuring independent financial decision-making without interference from shareholders[122] - The company has a complete internal management structure that operates independently from controlling shareholders[121] Environmental Management - The company has implemented strict environmental management practices, including obtaining necessary pollution discharge permits[169] - The pharmaceutical factory has been designated as a key wastewater discharge unit for 2024 in Chengdu, and has actively improved its environmental management level[172] - The company invested approximately 1.66 million yuan in environmental protection in 2024, covering clean production audits, online monitoring, and wastewater treatment operations[174] Shareholder Relations and Governance - The company held its first temporary shareholders' meeting in 2024 with a participation rate of 17.95% on January 31, 2024[123] - The company is committed to maintaining the legal rights of all shareholders through diligent board practices[143] - The board of directors approved a new compensation structure for executives, with an average increase of 15% in salaries[136] - The company has engaged in various investor relations activities to discuss business development and operational strategies throughout the reporting period[107] Strategic Commitments - The company has committed to avoiding any new competitive business activities with the listed company for a period of 5 years following the acquisition completion[182] - The company will take comprehensive measures, including asset injection and restructuring, to mitigate any potential adverse effects on the listed company due to overlapping business operations[182] - The company has pledged to avoid related party transactions with Taihe Health and its subsidiaries, ensuring fair and reasonable pricing[183]

Financial Performance - The company's revenue for Q1 2025 was CNY 126.91 million, a decrease of 29.21% compared to CNY 179.28 million in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of CNY 14.59 million, representing a decline of 740.09% from a profit of CNY 2.28 million in Q1 2024[6]. - The company reported a basic and diluted earnings per share of CNY -0.0234, a decrease of 750.00% from CNY 0.0036 in the same period last year[5]. - Total operating revenue decreased to ¥126,911,245.23 from ¥179,277,340.12, representing a decline of approximately 29.2% year-over-year[21]. - Net profit for the period was ¥-14,501,128.77, compared to a profit of ¥4,123,269.28 in the previous period, indicating a significant loss[22]. - Basic and diluted earnings per share were both ¥-0.0234, down from ¥0.0036 in the previous period[23]. Cash Flow and Operating Activities - The net cash flow from operating activities improved by 64.52%, with a net outflow of CNY 8.88 million compared to CNY 25.04 million in the previous year[5]. - Cash received from operating activities decreased by 85.97% to CNY 2.03 million, largely due to the previous year's receipt of development funds[12]. - The net cash outflow from operating activities was -$8,881,767.85, an improvement from -$25,035,659.98 in the previous period, indicating a reduction in cash burn[25]. - Cash inflow from operating activities totaled ¥203,075,400.26, down from ¥228,953,557.57, a decrease of approximately 11.3% year-over-year[24]. Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2.13 billion, down 5.26% from CNY 2.25 billion at the end of the previous year[5]. - The total assets decreased from 2,249,238,967.54 CNY to 2,130,996,832.61 CNY, a decline of approximately 5.3%[19]. - The total liabilities decreased from 1,200,000,000 CNY to 1,150,000,000 CNY, reflecting a reduction of about 4.2%[19]. - Total liabilities decreased to ¥1,077,403,955.40 from ¥1,181,257,849.14, a reduction of about 8.8%[20]. - Total equity attributable to shareholders decreased to ¥1,011,416,036.48 from ¥1,025,895,578.66, a decline of approximately 1.4%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,293[14]. - Sichuan Huasheng Group holds 17.87% of shares, amounting to 111,431,281 shares, with 89,033,593 shares pledged[14]. - The number of shareholders with more than 5% ownership remains stable, with no significant changes reported in the top 10 shareholders[15]. Operating Costs and Income - The company's operating costs decreased by 32.98% to CNY 66.81 million, primarily due to reduced business volume in the steel structure segment[11]. - Other income fell by 50.49% to CNY 2.44 million, mainly due to a reduction in government subsidies during the reporting period[11]. - Total operating costs decreased to ¥143,848,298.92 from ¥177,333,754.20, a reduction of about 18.9% year-over-year[21]. Investment and Financing Activities - The company reported a significant increase of 199.21% in cash received from financing activities, amounting to CNY 118.07 million, primarily due to financing lease receipts[13]. - Cash inflow from financing activities totaled $154,116,045.35, compared to $177,459,549.62 in the prior period, reflecting a decrease in financing received[25]. - The company reported a net investment loss of ¥-309,393.86, compared to a loss of ¥-1,114,592.88 in the previous period, indicating an improvement in investment performance[22]. Other Financial Metrics - Research and development expenses increased to ¥3,675,818.30 from ¥3,325,261.93, an increase of about 10.5% year-over-year[22]. - Cash paid to employees amounted to $33,626,517.12, an increase from $31,835,743.16, indicating rising labor costs[25]. - Cash paid for taxes was $25,301,530.36, a slight decrease from $27,121,071.62, suggesting improved tax efficiency[25]. - The company did not undergo an audit for the first quarter report, which may affect investor confidence in the financial statements[27].

证券代码：000790 证券简称：华神科技 成都华神科技集团股份有限公司 投资者关系活动记录表 编号：2025-001 答：公司重视新技术对生产效率和生产质量的提升，公司内 部组织了针对 AI 的专项培训，公司正在积极探索和布局中医药 数字化领域，将 AI 技术深入应用到研发、生产、销售、职能等 多项领域和业务，促进各个板块高效化和智能化，持续增强公司 市场竞争力。感谢您的关注。 问 2：出现业绩亏损的主要原因？ 答：公司 2024 年业绩亏损主要是以下几方面原因：首先，建 筑钢结构板块严控项目承接范围，聚焦筛选现金流稳健的优质项 目，导致该板块产值和利润确认较去年大幅减少；其次，山东凌 凯在建项目尚处于试生产调试阶段，未实现产品销售，产生折旧 摊销费用；再次，初步经评估需确认商誉减值，并据此计提了相 应的商誉减值准备；最后，2024 年公司坚定聚焦医药主业，医药 业务营业收入较去年增长，但由于市场竞争激烈，中药原材料采 购价格持续攀升，致使整体毛利率呈下滑态势。这些因素共同影 响了公司短期财务表现。感谢您的关注。 问 3：公司如何应对中药原材料价格波动，原材料成本不断 上涨的风险？ 答：您好，药材价格上涨影 ...

Financial Performance - The company expects a net loss of between 8 million and 15.5 million yuan for the fiscal year 2024, compared to a profit of 27.66 million yuan in the same period last year [2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of between 10 million and 19.5 million yuan, down from a profit of 35.42 million yuan last year [2]. Factors Affecting Profit - The decline in overall net profit is attributed to increased competition, rising procurement costs of traditional Chinese medicine raw materials, and a reduction in the scale of the construction steel structure business [4]. - The construction steel structure segment's output and profit recognition significantly decreased due to a focus on high-quality projects and a streamlined project scope [4]. - The Shandong Lingkai project is still in the trial production phase, resulting in depreciation and amortization expenses without product sales [4]. Goodwill and Financial Reporting - The company has preliminarily assessed the need to recognize goodwill impairment, leading to the provision for goodwill impairment [5]. - The financial data presented is a preliminary estimate by the company's finance department and has not yet been audited by an external auditor [6]. - Investors are advised to exercise caution as the specific financial data will be detailed in the 2024 annual report [6].

证券代码：000790 证券简称：华神科技 公告编号：2024-067 关于接受间接控股股东财务资助暨关联交易的公告 成都华神科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 为支持成都华神科技集团股份有限公司（以下简称"公司"或"华神科技"）经营发展 资金需求，公司间接控股股东四川星慧酒店管理集团有限公司（以下简称"星慧集团"） 拟向公司提供不超过6,000万元（含）的无息借款，根据实际经营情况，在借款有效期 限内随借随还，额度循环使用，借款有效期至2025年12月16日。 星慧集团为公司间接控股股东，根据《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第1号——主板上市公司规范运作》等相关规定，本次借 款事项构成关联交易，但属于公司接受关联人无偿提供财务资助，可豁免提交股东大会 审议。 公司于2024年12月23日召开了第十三届董事会第十九次会议、第十三届监事会第十 三次会议，会议审议通过了《关于接受间接控股股东财务资助暨关联交易的议案》，关 联董事已回避表决，全体非关联董事一致通过该议案。公司独立 ...

为支持公司经营发展资金需求，公司间接控股股东四川星慧酒店管理集团 有限公司拟向公司提供不超过 6,000 万元（含）的无息借款，公司不提供任何 担保，根据实际经营情况，在借款有效期限内随借随还，额度循环使用，借款 有效期至 2025 年 12 月 16 日。监事会认为：本次间接控股股东为公司发展提供 无息借款，公司不支付任何借款费用和不提供任何担保，符合公司根本利益。 关联监事苏蓉蓉女士回避表决。 证券代码：000790 证券简称：华神科技 公告编号：2024-066 成都华神科技集团股份有限公司 第十三届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届监事会第十 三次会议于2024年12月23日以现场表决的方式在公司会议室召开。本次会议通 知于2024年12月20日发出，本次会议应出席监事3人，实际出席监事3人。会议 由公司监事会主席苏蓉蓉女士主持。本次会议的召集、召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的有关规定。 二、 监事 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-065 成都华神科技集团股份有限公司 第十三届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第十九 次会议于2024年12月23日以现场与通讯表决相结合的方式在公司会议室召开。 本次会议通知于2024年12月20日发出，本次会议应出席董事9人，实际出席董事 9人。会议由公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的有关规定。 二、 董事会会议审议情况 关联董事黄明良先生、欧阳萍女士、HUANG YANLING 女士、杨苹女士、 王铎学先生回避表决。 具体内容详见公司在巨潮资讯网同日披露的相关公告。 表决结果：同意 4 票，反对 0 票，弃权 0 票，回避 5 票。 三、备查文件 1、公司第十三届董事会第十九次会议决议； 2、2024年第五次独立董事专门会议决议。 特此公告。 成都华神科技集团 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-064 成都华神科技集团股份有限公司 关于全资子公司为公司融资租赁业务提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2024 年 12 月 9 日，公司召开第十三届董事会第十八次会议，会议审议通过了《关于 公司办理融资租赁业务的议案》，同意公司向恒信天津申请办理融资租赁业务（包括售 后回租形式），融资总金额不超过 2,000 万元，期限 30 个月。公司全资子公司成都中医 大华神药业有限责任公司（以下简称"华神药业"）已履行其内部审批程序，华神药业为公 司上述融资租赁业务提供连带责任保证担保。 本次担保属于全资子公司为母公司提供担保，根据《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》的相关规定，本次全资子公司为母公司提 供担保事项无需提交公司董事会或股东会审议。 二、被担保人基本情况 8、经营范围：高新技术产品开发生产、经营；中西制剂、原料药的生产（具体经营项 目以药品生产许可证核定范围为准，并仅限于分支机构凭药品生产许可证在有效期内从事 1、公司名称 ...

证券代码：000790 证券简称：华神科技 公告编号：2024-063 成都华神科技集团股份有限公司 第十三届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、审议通过《关于公司办理融资租赁业务的议案》 董事会同意公司拟向海通恒信国际融资租赁（天津）有限公司（以下简称 "恒信天津"）申请办理融资租赁业务（包括售后回租形式），融资总金额不超 过 2,000 万元，期限 30 个月，具体权利义务条款以公司与恒信天津签署的相关 融资租赁合同及文件中的约定为准。同意授权董事长（法定代表人）或其指定 的授权代理人签署授信相关文件及办理有关手续。 根据《公司章程》的规定，上述事项在公司董事会的审批权限范围内，无 需提交公司股东大会审议。根据上述融资租赁机构要求，由公司全资子公司成 都中医大华神药业有限责任公司（以下简称"华神药业"）为公司上述融资租赁 业务提供连带责任保证担保，担保类型、担保范围、担保期间及担保责任等具 体事项以华神药业与恒信天津签署的相关担保合同及文件中的约定为准。本次 担保事项系公司全资子公司为公司提供担保，不属于对外担保 ...

特此公告。 成都华神科技集团股份有限公司 董 事 会 二〇二四年十月三十一日 成都华神科技集团股份有限公司（以下简称"公司"）董事会于近日收到公司 总裁宋涛先生的书面辞职报告。宋涛先生因个人职业发展规划原因申请辞去公司 总裁职务，辞职后不再担任公司及下属子公司的任何职务，该辞职报告自送达公 司董事会之日起生效，其辞职不会影响公司相关工作的正常进行。在总裁职位空 缺期间，将由董事长黄明良先生代行总裁职责。 截至本公告披露日，宋涛先生未直接或间接持有公司股份，亦不存在应当履 行而未履行的承诺事项。宋涛先生在担任公司总裁期间勤勉尽责、恪尽职守，公 司及董事会对宋涛先生在公司任职期间所做出的贡献表示衷心的感谢！ 证券代码：000790 证券简称：华神科技 公告编号：2024-062 成都华神科技集团股份有限公司 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...